PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25588857-10	2015	CONCLUSIONS: The results of our present study demonstrated that AR remained in the majority of metastatic samples from AR-positive primary TNBCs and that AR manipulation could be exploited in the metastatic settings of TNBC.	tnbcs	139-144	androgen receptor	Homo sapiens	119-121	
27058032-5	2016	Despite lower pathologic complete response (pCR) rates with neoadjuvant therapy, patients with AR-dependent TNBCs have a better prognosis than those with TNBCs that are not AR-dependent.	tnbcs	108-113	androgen receptor	Homo sapiens	95-97	
25588857-10	2015	CONCLUSIONS: The results of our present study demonstrated that AR remained in the majority of metastatic samples from AR-positive primary TNBCs and that AR manipulation could be exploited in the metastatic settings of TNBC.	tnbcs	139-144	androgen receptor	Homo sapiens	64-66	
25588857-10	2015	CONCLUSIONS: The results of our present study demonstrated that AR remained in the majority of metastatic samples from AR-positive primary TNBCs and that AR manipulation could be exploited in the metastatic settings of TNBC.	tnbcs	139-144	androgen receptor	Homo sapiens	119-121	
25145503-3	2015	RESULTS: AR expression was found in 17.7% (87/492) of TNBCs.	tnbcs	54-59	androgen receptor	Homo sapiens	9-11